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Abstract
Background: One of the hallmarks of cancer is the disruption of gene expression patterns. Many molecular lesions
contribute to this phenotype, and the importance of aberrant DNA methylation profiles is increasingly recognized.
Much of the research effort in this area has examined proximal promoter regions and epigenetic alterations at
other loci are not well characterized.
Results: Using whole genome bisulfite sequencing to examine uncharted regions of the epigenome, we identify a
type of far-reaching DNA methylation alteration in cancer cells of the distal regulatory sequences described as
super-enhancers. Human tumors undergo a shift in super-enhancer DNA methylation profiles that is associated with
the transcriptional silencing or the overactivation of the corresponding target genes. Intriguingly, we observe locally
active fractions of super-enhancers detectable through hypomethylated regions that suggest spatial variability
within the large enhancer clusters. Functionally, the DNA methylomes obtained suggest that transcription factors
contribute to this local activity of super-enhancers and that trans-acting factors modulate DNA methylation profiles
with impact on transforming processes during carcinogenesis.
Conclusions: We develop an extensive catalogue of human DNA methylomes at base resolution to better
understand the regulatory functions of DNA methylation beyond those of proximal promoter gene regions. CpG
methylation status in normal cells points to locally active regulatory sites at super-enhancers, which are targeted by
specific aberrant DNA methylation events in cancer, with putative effects on the expression of downstream genes.
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Background
The naked DNA sequence alone cannot explain the
different cellular functions or phenotypes of cells and or-
ganisms with identical genetic sequences, such as the
presence of different tissues within the same individual
[1], monozygotic twins [2], and cloned animals [3]. This
is even more pertinent when we try to explain the
pathophysiology of the most common human diseases
with their multifactorial causes. The existence of differ-
ent chemical marks, such as DNA methylation and post-
translational modifications of histones, that regulate
gene activity in the epigenetic layers has taken center
stage in biology and medicine [4]. However, many stud-
ies have taken a biased approach in examining the regu-
latory sequences nearest to the transcriptional start sites
of the studied genes and, with rare exceptions [5–7],
other potentially important regions have been neglected
in attempts to address the role of epigenomics in tissue
identity and disease. In this context, the existence of
super-enhancers [8] or locus control regions [9, 10],
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large clusters of transcriptional enhancers that drive ex-
pression of genes that define cell identity, has been de-
scribed. Most importantly, disease-associated variation is
especially enriched in the super-enhancers of the cor-
responding cell types [11], and new super-enhancers
for oncogenes and other transforming genes have
been identified in cancer cells [12–15]. Herein, we
present human DNA methylomes at single-nucleotide
resolution of normal and cancer cells to identify
epigenetic shifts in super-enhancers associated with
these diseases.
Results and discussion
We performed whole genome bisulfite sequencing
(WGBS) to obtain unique DNA methylation data sets
for five normal tissues and eight associated cancer sam-
ples (Table 1). Normal samples (n = 5) included brain,
blood (CD19+), breast, lung and colon specimens. In
order to enable the analysis of DNA methylation vari-
ance from different perspectives, we produced references
data sets for cancer samples that involved both primary
tumors (n = 2) and cancer cell lines (n = 6). These in-
cluded a donor-matched primary colon triplet (normal
tissue, primary cancer, liver metastasis) and matched pri-
mary and metastasis breast cancer cell lines, enabling us
to analyze changes during tumor progression. The epi-
genetic peculiarities that could be present in cancer
cell lines were addressed through replication experi-
ments in an additional set of 78 normal tissue samples
and 714 primary tumors using the HumanMethylation450
BeadChip (Table 2). The obtained data were also validated
using the DNA methylation microarray profiles avail-
able for 208 normal samples and 675 primary tumor
samples in The Cancer Genome Atlas (TCGA) pro-
jects (Table 2) [16–18].
Aligning uniquely mapping bisulfite sequencing reads
(mean ~480 million reads per sample) of the original 13
samples undergoing whole genome single-nucleotide
resolution analysis resulted in a median genomic cover-
age of 11.1× (14.1× CpG coverage) per sample. Consist-
ent with previous reported results, apart from bimodal
DNA methylation levels at promoter sites, the genomes
presented high methylation levels, which were globally
reduced in cancer samples (Table S1 and Figure S1 in
Additional file 1) [5, 6]. To estimate the relationship
between super-enhancers and DNA methylation levels,
we determined DNA methylation profiles for enhancer
regions within their respective tissue types. From the
super-enhancers previously described in our normal tis-
sue types through the histone modification H3K27ac
(identified as a superior and sufficient mark for the iden-
tification of super-enhancers [11]), we could examine
99.3 % (5128 of 5163; >50 % CpGs covered; Table S1 in
Additional file 1) using our WGBS data. We found sig-
nificant enrichment of unmethylated DNA sequences
within the super-enhancers compared with the flanking
genomic regions (Fisher’s exact test, odds ratio (OR) 5.6,
p < 0.001), supporting the relevance of the features in
the here interrogated context. In particular, the edges of
the enhancers were CpG-unmethylated, clearly marking
the boundaries of the regulatory regions (Fig. 1a, b), a
phenomenon that was consistent throughout the ana-
lyzed tissue types (Figure S2 in Additional file 1) and
that could not be observed in traditional enhancers
(Figure S3a, b in Additional file 1) [11]. Moreover,
super-enhancers were significantly more hypomethylated
Table 1 Whole genome bisulfite sequencing of 13 human samples
Sample ID Status Tissue Origin Total
reads
Coverage
genome
Coverage
CpG
Average
methylation
SEa SE
coveredb
CD19 Normal B cells Primary 318714023 6.0 14.1 76.0 688 99.0 %
Brain Normal Brain (white matter) Primary 557237398 11.1 7.0 77.1 1067 99.6 %
Breast Normal Breast Primary 606872747 15.1 32.1 73.0 1099 99.5 %
Colon Normal Colon Primary 609043678 13.7 24.3 69.6 1023 99.4 %
Lung Normal Lung Primary 333333332 7.2 8.7 74.4 1286 99.1 %
Colon_P Cancer Colorectal cancer Primary 670281443 16.7 24.6 66.5 1023 99.4 %
Colon_M Cancer Colorectal cancer metastasis Primary 652566967 16.3 24.7 62.4 1023 99.4 %
MDA-MB-468PT Cancer Breast cancer Cell line 626288553 15.4 37.6 57.1 1099 99.4 %
MDA-MB-468LN Cancer Breast cancer metastasis Cell line 600134926 14.3 37.1 42.8 1099 99.5 %
U87MG Cancer Glioblastoma Cell line 281524883 6.3 8.5 55.7 1067 99.6 %
H1437 Cancer Lung adenocarcinoma Cell line 333333332 7.9 10.3 48.1 1286 99.1 %
H1672 Cancer Small cell lung cancer Cell line 329691560 7.4 10.5 65.6 1286 99.1 %
H157 Cancer Lung squamous cell cancer Cell line 333333332 7.8 10.7 41.8 1286 99.2 %
aSE is the number of super-enhancer regions determined in the respective normal tissue samples [11]
bSE covered is the percentage of super-enhancers covered by WGBS (>50 % of CpG sites)
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than traditional enhancers (Fisher’s exact test, OR 1.8,
p < 0.001), further supporting DNA methylation to
specifically indicate functionality in this enhancer
subtype.
The fact that super-enhancer edges show lower DNA
methylation levels compared with their center could be
related to an enrichment of transcription factor binding
sites at the extreme parts of the regions (Fisher’s exact
test, OR 5.33, p = 1.0 × 10−11; Figure S3c in Additional
file 1) [19]. Indeed, DNA hypomethylation and tran-
scription factor occupancy revealed a significant rela-
tionship (Fisher’s exact test, OR 11.3, p = 2.2 × 10−16;
Figure S3d in Additional file 1), consistent with previous
reports describing a co-dependency of both regulatory
mechanisms [20, 21].
The extent of tissue-specific DNA methylation dif-
ferences in the super-enhancer regions was low, with
only 12.6 % (644 out of 5111) of them showing CpG
methylation differences from different normal tissues
(δ hypomethylated regions (HMRs) occupancy >10 %;
Supplementary methods, Figure S4a and Table S2 in
Additional file 1). We assessed variance in super-
enhancer DNA methylation profiles by differential
analysis of HMRs, focal sites of low DNA methylation
levels that mark active regulatory loci [22–24], to ac-
count for the high heterogeneity at the large genomic
regions represented by super-enhancers. Remarkably,
tissue-specific HMRs at breast and blood super-enhancers
were significantly enriched in specific transcription factor
binding within the respective tissues, as measured by
the occupancy of ten commonly profiled factors de-
termined in CD19+ (GM12878; Fisher’s exact test,
OR = 2.81, p < 0.001) and breast cells (MCF7; Fisher’s
exact test, OR = 1.64, p = 0.007) [19]. Moreover, super-
enhancers with tissue-specific DNA methylation levels
in breast and brain samples were enriched at promoter re-
gions compared with non-specific super-enhancers, in
contrast to previous results that suggest tissue-specific
DNA methylation to be enriched in cis-elements (Fisher’s
exact test, OR 6.64, p < 0.001 and OR 1.74, p = 0.018, re-
spectively; Figure S4b in Additional file 1) [1]. The sample
with the greatest DNA methylation difference compared
with normal tissues was that of the CD19+ cell-
related super-enhancers (ANOVA, p < 0.001; Figure
S4c in Additional file 1), which was the only repre-
sentative of a non-solid tissue type. It is of note that
the presence of tissue-specific DNA methylation in this
minor fraction of super-enhancers could be validated by
genome-scale analysis using DNA methylation microar-
rays (HumanMethylation450 BeadChip). Of the normal
tissue-derived super-enhancers, 75.5 % (486 of 644) were
represented by at least three probes, in a unique set of 78
normal samples (Table 2), representing the analyzed tissue
types, of which 71.4 % (347 of 486) showed significant
difference between the respective tissue types (Student’s
t-test, false discovery rate (FDR) < 0.05; Figure S4d
and Table S3 in in Additional file 1). As examples of
super-enhancer tissue-specific DNA methylation we
can cite the genes encoding the RNA-binding protein
QKI (involved in myelinization and oligodendrocyte
differentiation), which is unmethylated in white brain
matter but heavily methylated in all other normal tissues
(Figure S5a in Additional file 1), and lymphoblastic
leukemia-associated hematopoiesis regulator 1 (LYL1; plays
a role in blood vessel maturation and hematopoiesis), which
is unmethylated in CD19+ cells but hypermethylated in all
other normal tissues (Figure S5b in Additional file 1).
From the 5111 super-enhancers studied we established
four categories based on their average DNA methylation
levels (Fig. 1b, c). Remarkably, we determined striking
Table 2 Genome-scale DNA methylation analysis of 78 normal tissue samples, 714 primary tumors and 24 metastasis samples
(HumanMethylation450 BeadChip) and combined expression/DNA methylation analysis of 208 normal and 675 primary tumor
samples (TCGA)
Cancer type Status Origin Number of samples Number of samples TCGA
Lung Normal Primary sample 26 57
Colon Normal Primary sample 18 41
Breast Normal Primary sample 19 110
Brain (white matter) Normal Primary sample 10 -
Blood (CD19+) Normal Primary sample 5 -
Lung adenocarcinoma Cancer Primary sample 321 216
Lung squamous cell carcinoma Cancer Primary sample 120 -
Colorectal cancer Cancer Primary sample 103 258
Colorectal cancer metastasis Metastasis Primary sample 24 -
Breast cancer Cancer Primary sample 66 201
Small cell lung cancer Cancer Primary sample 56 -
Glioblastoma Cancer Primary sample 48 -
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Fig. 1 DNA methylation profile of super-enhancer regions derived from normal tissues determined by whole genome bisulfite sequencing
(WGBS). a Scaled DNA methylation profile of 5111 super-enhancers (SE) in their respective normal tissues (n = 5). Each super-enhancer is
represented by a single line (blue) and smoothed DNA methylation levels inside the super-enhancer (black bar) and equally sized flanking
sequences (gray bar) are displayed. b DNA methylation levels of super-enhancers in their respective normal tissues (n = 5) in equally sized
windows (green, 0 %; red, 100 %). Each horizontal line represents a single super-enhancer, ordered by average DNA methylation levels. Super-enhancers
are grouped according to their average DNA methylation levels (red, <25 %; blue, <50 %; green, <75 %; purple, <100 %). c Smoothed average DNA
methylation profile of all super-enhancers categorized into four groups on the basis of DNA methylation levels. d Examples of the DNA methylation
profiles of breast super-enhancers representing the defined subgroups. Genomic locations of the super-enhancers (dashed vertical lines) and
equally sized flanking regions are displayed and CpG dinucleotides locations are indicated (bottom, colored bars). e Association between
DNA methylation levels and H3K27ac peak signals [11] in normal breast tissues and breast super-enhancers (n = 1091) displayed as
averaged values (50-bp windows). Super-enhancers were classified into previously defined subgroups. f Gene expression levels of target
transcripts in normal breast tissues. Scaled averaged expression levels of genes associated with breast super-enhancers (n = 1091) in
normal breast tissue samples (n = 110; TCGA [16]). Super-enhancers were grouped according to their average DNA methylation levels.
Significance of a Spearman’s correlation test is indicated. RSEM RNA-Sequencing by Expectation Maximization
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differences between DNA methylation profiles at super-
enhancers, ranging from fully hypermethylated to com-
pletely unmethylated (Fig. 1d). Moreover, focal hypo-
methylated regions pointed to spatial differences in
DNA methylation within super-enhancers, suggesting
local variability in their activity. Accordingly and in con-
trast to previous assumptions, the focal variability of the
here studied epigenetic mark supports the action of in-
dependent regulatory units and challenges the conjoint
activity of enhancer clusters for this subset of super-
enhancer regions.
From an epigenetic perspective, the CpG unmethylated
status was significantly correlated with H3K27ac occu-
pancy (Spearman’s correlation test, rho 0.535, p < 0.001;
Fig. 1e) and, to a lesser extent, with H3K4me1 (Spear-
man’s correlation test, rho 0.278, p < 0.001), further sup-
porting the former mark as sufficiently bookmarking
super-enhancer functionality. This association was inde-
pendent of the local CpG density, suggesting a sequence-
independent connection between the two epigenetic
marks (multivariate linear model, p < 0.001; Figure S6 in
Additional file 1). Most importantly, unmethylated status
was significantly associated with increased transcriptional
activity of the regulated target genes, indicating that DNA
methylation levels at these sequences may be of value
as surrogate marks of super-enhancer functionality
(Spearman’s correlation test, rho −0.77, p < 0.001;
Fig. 1f ). Although, functional DNA methylation vari-
ance at enhancer sites has been reported previously
[25–28], we observed a stronger effect of differential
DNA methylation on gene expression levels of super-
enhancer-related targets (Figure S7a in Additional file 1).
It is of note that the increased correlation between DNA
methylation and gene expression at super-enhancers com-
pared with traditional enhancers was observed for enhan-
cer sites overlapping promoter regions and those distal to
the target gene transcription start site (TSS), suggesting
an elevated effect of differential super-enhancer DNA
methylation independent of the distance to its target
(Figure S7a in Additional file 1). Moreover, DNA
methylation levels at super-enhancers overlapping
promoters showed significantly higher correlation at
regions flanking the proximal (±2 kb of the TSS) pro-
moter (Spearman’s correlation test, rho 0.26 versus
0.18), further suggesting that enhancer-specific dynamics
drive gene regulation. It is noteworthy that we did not ob-
serve a correlation between super-enhancers and target
promoter-related CpG island DNA methylation levels
(Spearman’s correlation test, rho 0.0001, p = 0.99), al-
though both genomic features independently correlated
significantly with gene expression (Spearman’s correlation
test, rho 0.31, p < 0.001 and rho 0.16, p < 0.001, respect-
ively), suggesting an independent function of both regula-
tory elements. Furthermore, the effect of enhancers on
gene expression was closely related to the enhancer size,
with DNA methylation levels at super-enhancers present-
ing the highest correlation with target gene expression
compared with smaller sized counterparts (Figure S7b in
Additional file 1).
For cis-acting super-enhancers, we observed that
the assignment of the closest gene as target resulted
in better correlations between super-enhancer DNA
methylation and gene expression than a chromatin
conformation-based method (ChIA-PET Pol2 in MCF-7
cells, Spearman’s correlation test, rho −0.048, p = 0.4;
Figure S7c in Additional file 1) [29]. However, both strat-
egies clearly include falsely assigned enhancer–target pairs
and more suitable methodologies have yet to be defined.
Aberrant DNA methylation profiles of super-enhancers in
human cancer
Considering the association between DNA methylation
status and super-enhancer activity in normal tissues, we
wondered whether the observed epigenetic pattern was
significantly altered in human cancer. We observed that
14 % (727 out of 5111) of the super-enhancers studied
underwent CpG methylation changes in their respective
human tumor types, e.g., normal breast versus breast
cancer cell lines (Fig. 2a). The most common DNA
methylation shift was the loss of CpG methylation in the
cancer sample, which was noted in 75.4 % (548 of 727)
of cases, whilst 24.6 % (179 of 727) of super-enhancers
gained DNA methylation across the eight tissue-
matched cancer samples (δ HMR occupancy >25 %;
Fig. 2a; Figure S8a and Tables S4 and S5 in Additional
file 1). Interestingly, the hypomethylation events were
rather unspecific, as they were associated with the global
loss of DNA methylation usually observed in cancer
samples (paired t-test, p > 0.05) [5, 6, 30], the only not-
able exception being colorectal tumors, in which they
were significantly super-enhancer locus-specific (average
flanking regions versus super-enhancer reduction 29.8 %
[tumor] and 33.9 % [metastasis], paired t-test, p < 0.001;
Figure S8b and Table S5 in Additional file 1). Thus, to
determine functional epigenetic alterations, we decided
to initially focus on the hypermethylated events, which
were enriched in genes associated with transcriptional
and metabolic processes and angiogenesis (FDR < 0.01;
Table S6 in Additional file 1). Importantly, hyperme-
thylation events were also replicated using DNA
methylation microarray analyses in a unique cohort of
714 primary cancer samples (Table 2 and Fig. 2b),
where 58.1 % (68 of 117) of the interrogated DNA
hypermethylation events at super-enhancers were con-
firmed (Student’s t-test, FDR < 0.05; Fig. 2c; Table S7 in
Additional file 1). These results further suggest that the
hypermethylation events observed in the cancer cell line
models are mirroring altered DNA methylation profiles at
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super-enhancer regions in primary tumors. Hypermethy-
lated super-enhancers in cancer included genes previously
related to cellular transformation (e.g., CIC, FOXA2,
FOXP1, RUNX1 and TBX3) [31]. Importantly, we ex-
cluded that copy number variations (CNVs) have con-
founded our analysis of the primary cancer samples by
detecting significant differences in DNA methylation
levels between normal and CNV samples in only a very
minor fraction of the super-enhancers (4.3 %, 5/117; Stu-
dent’s t-test, FDR < 0.05; Table S7 in Additional file 1).
It is of note that, using oxidative bisulfite (ox-BS)
treatment coupled with DNA methylation microarray
analyses, we could exclude the gain of DNA methyla-
tion observed in cancer to be due to an increase of
5-hydroxy methylation (5-hmC), a specific cytosine
modification that confounds with 5-methylation (5-mC)
in bisulfite (BS)-based analyses and found to be enriched
in traditional enhancer regions (Figure S9 in Additional
file 1) [32]. In order to test a significant contribution of
the 5-hmC to the methylation gain in super-enhancers,
we compared the methylation values obtained from BS-
treated against ox-BS-treated cancer samples, enabling us
to estimate the 5-hmC levels [33]. With the alternative hy-
pothesis being that the ox-BS values were greater than 0,
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we did not observe a significant presence of 5-hmC in any
cancer sample (paired one-tailed Wilcoxon test).
To further elucidate the functional consequences asso-
ciated with the identified cancer-specific super-enhancer
DNA methylation shifts, we investigated the impact of
the tumor-associated gains of super-enhancer DNA
methylation on gene expression. We first used a breast
cancer model that included the paired breast cancer cell
lines MDA-MB-468PT (derived from the primary
tumor) and MDA-MB-468LN (derived from a lymph
node metastasis) and the untransformed immortalized
breast epithelial cell line MCF10A, associating differen-
tial gene expression (RNA sequencing, RNA-seq) with
super-enhancer DNA methylation levels. As has been
observed for the proximal regulatory gene regions,
where a general repressive effect of DNA methylation is
widely recognized [34], we found an association between
DNA methylation gain in breast super-enhancer regions
and gene repression of the associated genes for both
MDA-MB-468PT (Spearman’s correlation test, rho −0.25,
p = 0.026) and MDA-MB-468LN (Spearman’s correlation
test, rho −0.3, p = 0.002; Fig. 2d) cell lines.
We extended these observations to primary breast tu-
mors from the TCGA [16], whose expression patterns
have also been determined by RNA-seq. We confirmed
the significant association between the DNA methylation
gains of super-enhancers identified in our breast cancer
cell line data set and gene repression observed in the
matched TCGA breast cancer samples (Spearman’s cor-
relation test, rho −0.24, p = 0.01; Fig. 2e). Interestingly,
the super-enhancers that became hypermethylated in
breast cancer were those that, in normal breast epithelial
cells, were the most enriched in the H3K27ac histone
mark (Spearman’s correlation test, rho 0.2, p < 0.001;
Fig. 2f ), which defines these particular distal regulatory
regions [8, 11, 13], and the H3K4me1 enhancer mark
(Spearman’s correlation test, rho 0.2, p < 0.001). Remark-
ably, the most hypermethylated super-enhancers had
also the highest level of expression for the respective as-
sociated genes in normal breast epithelial cells (linear
slope 1.23, p < 0.001; Fig. 2g).
We were able to validate the link between cancer-
specific super-enhancer hypermethylation and the tran-
scriptional inactivation of the corresponding genes be-
yond the breast tumor type. In the lung tumorigenesis
samples from the H1437 (lung adenocarcinoma) and
H157 (lung squamous cell carcinoma) cancer cell
lines, we found evidence that lung super-enhancer gain of
DNA methylation was associated with the downregulation
of the target genes (linear slope −3.06, p < 0.001 and
−2.09, p = 0.004, respectively; Figure S10a, b in Additional
file 1) determined by publically available expression mi-
croarrays [35]. We also extended these findings to primary
lung adenocarcinoma and lung squamous cell carcinoma
tumors from the TCGA [18], in which expression of the
candidate genes originates from RNA-seq experiments. In
this setting, we observed a significant association between
lung super-enhancer hypermethylation identified in
our lung cancer cell lines and gene downregulation
found in the matched primary lung cancer samples
(Spearman’s correlation test, rho −0.19, p = 0.012 and
rho −0.25, p < 0.001, respectively; Figure S10c, d in
Additional file 1). The significant association between
cancer-specific DNA methylation of super-enhancers
and gene repression was also noted in the glioblast-
oma cell line U87MG (Spearman correlation test, rho
−0.26, p < 0.001; Figure S10e in Additional file 1), in
which we performed an expression microarray experi-
ment. Thus, the results overall suggest that a tumor-
related gain of DNA methylation in super-enhancers
has a transcriptionally repressive effect on the corre-
sponding related genes.
We next considered the commonality among differ-
ent tumor types within super-enhancer DNA methyla-
tion changes, and the type of genes and pathways
affected by these aberrant epigenetic shifts. We first
observed that within regions of commonly hypo-
methylated super-enhancers in normal contexts, the
cancer samples (Table 2) clustered by tumor type
(Fig. 3a), a phenomenon we previously identified for
DNA methylation events in proximal promoters among
distinct human tumors [36]. Interestingly, despite the clear
presence of super-enhancer DNA methylation that is asso-
ciated with the cancer type, there are hypermethylated
super-enhancers shared by common epithelial tumors
such as the breast and lung samples (Figure S11a in
Additional file 1). This is the case for the super-enhancer
of the tumor suppressor microRNA MIRLET7, where hy-
pomethylation of the super-enhancer was diminished by a
gain of CpG methylation in a fraction of the regulatory re-
gion (Fig. 3b, c; Figure S11b, c in Additional file 1). It is of
note that the large highly hypomethylated super-enhancer
regions displayed focal gains in DNA methylation in can-
cer, suggesting that distinct segments might exhibit spe-
cific functions in healthy and cancer contexts. Consistent
with the suspected regulatory function, hypermethylation
of the MIRLET7-associated super-enhancer region was
associated with transcriptional silencing of MIRLET7B
and MIRLET7A3, two family members coded within the
affected pri-microRNA (Figure S11d in Additional file 1).
Moreover, microRNAs MIRLET7B and MIRLET7A3
were repressed in primary breast carcinomas (TCGA
[16]; Wilcoxon test, p = 0.001 and p = 0.033, respect-
ively) and lung adenocarcinomas (TCGA [18]; Wilcoxon
test, p < 0.001 and p < 0.001, respectively) (Figure S11e, f
in Additional file 1) and hypermethylation at super-
enhancers was significantly correlated with microRNA re-
pression in breast carcinomas (Spearman correlation test,
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rho −0.4 and −0.42, p < 0.001 and p < 0.001, respectively)
and lung adenocarcinomas (Spearman correlation test,
rho −0.47 and − 0.3, p < 0.001 and p < 0.001, respectively)
(Fig. 3d, e).
Cancer-specific super-enhancers coincide with regional
hypomethylation
Until now we have focused our attention on those se-
quences described as being super-enhancers that ensure
cell and tissue identity in normal tissues [8, 11]. How-
ever, a new class of super-enhancer sequences has re-
cently been described that only play this de novo
regulatory role in transformed cells to drive the cancer
phenotype and its associated hallmarks [11, 13, 37]. We
examined the DNA methylation changes occurring in
the super-enhancers of colorectal cancer (HCT-116, n
= 387), in which we obtained 99 % coverage using
our WGBS approach. We observed that these newly
developed tumor-related super-enhancers were associ-
ated with DNA hypomethylation events (n = 23, δ
HMR occupancy >25 %) at these sequences in the
transformed cells compared with normal colorectal
mucosa (Fig. 4a; Table S8 in Additional file 1). Most
notably, the super-enhancer hypomethylation shift was
independent of the global loss of DNA methylation
generally found in cancer cells (paired t-test, p < 0.001)
[5, 6, 30] and rather represented a focal DNA demeth-
ylation event within the super-enhancer regions (Figure
S12 in Additional file 1). As we did with the aforemen-
tioned normal tissue super-enhancers, we validated the
DNA hypomethylation changes in these de novo cancer
super-enhancers using a cohort of matched normal
colon and primary colorectal tumors (TCGA [17], n = 41)
analyzed by DNA methylation microarrays (Fig. 4a;
Table S8 in Additional file 1). Noteworthy, we again
excluded potential biases included by CNV in these
regions (Table S8 in Additional file 1). In this setting,
we further confirmed that the loss of DNA methyla-
tion in these emerging cancer super-enhancers was
significantly associated with an increase in expression
of the corresponding regulated genes in the primary
colon tumors in comparison with the matched normal
colon mucosa (TCGA [17]; Spearman’s correlation test,
rho −0.18, p = 0.009; Fig. 4b). Examples within the most
hypomethylated cancer super-enhancers include those se-
quences regulating the MYC and RNF43 [38] oncogenes
(Fig. 4c; Figure S13a, b in Additional file 1), regions not af-
fected by CNV in the primary colorectal cancer sample
analyzed by WGBS (Table S8 in Additional file 1). Import-
antly, DNA methylation changes affected solely regions
specifically marked by H3K27ac in colon cancer and
widely excluded H3K4me3, further indicating that alter-
ations in super-enhancers occur predominantly distal to
the core promoter regions (Fig. 4c).
An interesting matter arising from these results is their
value for identifying putative mechanisms that create
such specific patterns of oncogenic super-enhancer hy-
pomethylation. It has been proposed that the availability
and binding of transcription factors (TFs) to regulatory
regions might be able to impact on the DNA methylome
and that it is not the transcriptional activity per se that
alters the DNA methylation profile of regulatory ele-
ments [20, 21]. Herein, we have studied the putative
enrichment of TF binding sites in these colorectal
cancer-specific hypomethylated enhancers and we ob-
served a significant enrichment for specific TF binding
motifs (Figure S14a in Additional file 1). From these fac-
tors, specifically FOXQ1 (forkhead box Q1; p = 0.013), a
member of the FOX gene family that is involved in
tumorigenesis [39], was the most overexpressed TF in
primary colorectal cancer samples and showed multiple
binding sites (Table S8 in Additional file 1) and a signifi-
cant enrichment at hypomethylated super-enhancer loci
(Figure S14b in Additional file 1). In relation to this
point, FOXQ1 had a 73-fold greater expression in pri-
mary colorectal cancer samples than in matched control
samples (TCGA [17]; Wilcoxon test, p < 0.001; Fig. 4d).
Furthermore, the stronger FOXQ1 expression was
significantly associated with hypomethylation of the
previously defined super-enhancers (linear slope −3.74,
p = 0.008; Fig. 4e) and the activation of associated target
genes (linear slope 0.14, p < 0.001; Fig. 4f ), such as the
well-known oncogenes MYC and RNF43 (Figures. S15a,
b and S16a, b in Additional file 1). Interestingly, the
presence of cancer-specific super-enhancer hypomethy-
lation and the tumorigenic effect mediated by the pres-
ence of FOXQ1 binding sites could be useful for
identifying new candidate oncogenes, such as GPRC5A
(G protein-coupled receptor, class C, group 5, member
A; Figures. S13c, d, S15c and S16c in Additional file 1),
which, by mediating between retinoid acid and G pro-
tein signaling pathways, has a role in epithelial cell dif-
ferentiation [40].
Importantly, we experimentally validated the associ-
ation between FOXQ1 expression and target gene regu-
lation in a colorectal cancer cell line model system
(HCT116 and SW1116 cancer cell lines). Initially, we
confirmed the occupancy of FOXQ1 at binding sites
within the super-enhancer regions of the previous de-
scribed target genes MYC, RNF43 and GPRC5A (Figure
S17a in Additional file 1). Furthermore, following small
hairpin RNA (shRNA)-mediated knockdown of the TF,
we observed significant downregulation of MYC, RNF43
and GPRC5A, suggesting a direct regulatory role of
FOXQ1 (Figure S17b in Additional file 1). In line with
the oncogenic role of FOXQ1 targets in colorectal can-
cer settings, knockdown of the TF reduced cell prolifera-
tion of the colorectal cancer cell line (Figure S17c in
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Additional file 1). Remarkably, in addition to FOXQ1,
we could also experimentally confirm the regulatory ef-
fect of other enriched TFs, whose expression correlated
significantly with super-enhancer hypomethylation level
(p < 0.05; Figure S14b in Additional file 1). Specifically,
we experimentally confirmed the regulatory effect of the
TFs HNF4A and PPARG on RNF43 and GPRC5A ex-
pression (Figure S18a, b in Additional file 1). Herein,
knockdown of the TFs repressed RNF43 and GPRC5A
expression (Figure S18c in Additional file 1) and resulted
in reduced cell viability (Figure S18d in Additional
file 1), further supporting the accuracy of the functional
prediction based on super-enhancer DNA methylation
levels (Figure S14b in Additional file 1).
Further, we were interested if disruption of the super-
enhancer structure would interfere with the DNA
methylation levels in the respective regions. Therefore,
we treated the colorectal cancer cell lines HCT116 and
SW1116 at sub-lethal concentrations with the BET-
bromodomain inhibitor JQ1, a small molecule targeting
BRD4, a key component of the secondary super-
enhancer structure (Figure S19a, b in Additional file 1)
[13]. Interestingly, although the treatment with JQ1 de-
creased the expression of super-enhancer gene targets,
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such as MYC, RNF43 or GPRC5A, we could not detect
an effect on DNA methylation levels at super-enhancer-
related CpG sites (Figure S19c, d in Additional file 1).
The lack of DNA methylation variance following JQ1
treatment suggests that the secondary super-enhancer
structure per se is not a determinant of DNA methyla-
tion profiles, but that it is the binding of TFs to the
DNA that locally establishes CpG methylation levels.
Large-scale hypomethylation marks potential
cancer drivers
Finally, we wondered whether DNA methylation data
obtained from WGBS could be used to identify new can-
didate cancer regulatory regions beyond the histone-
based super-enhancer loci [8, 11]. In line, extended
hypomethylated regions were previously established as
important regulatory elements in hematopoietic cells
with a function in leukemogenesis [41]. To test this hy-
pothesis, we ranked all the de novo formed hypomethy-
lated DNA regions (<20 % average DNA methylation) in
our colorectal cancer samples by size, having shown
above that HMRs in colorectal tumorigenesis presented
locus-specific properties (Figure S8b and Table S5 in
Additional file 1). In this setting, we did observe an un-
equal distribution of HMR sizes, as previously reported
for the super-enhancer-defining mark H3K27ac (Fig. 5a).
Importantly, these large HMRs were mutually exclusive
to the presence of super-enhancers in the respective
regions, suggesting they represent an independent
epigenetic feature to histone defined regulatory ele-
ments. Intriguingly, large HMRs mainly spanned gene
promoter regions (22/26; Table S9 in Additional file 1), a
phenomenon previously described for genes activated in
medulloblastoma patients, where an extensive expanded
hypomethylation beyond the proximal promoter was
observed, which might be a general feature of cancer-
related gene activation [42]. Further, most of the HMRs
that were present only in the metastatic cancer samples
presented features suggesting a role in tumorigenesis.
For example, the largest observed HMR (34.1 kb) in the
metastatic colorectal cancer sample corresponded to
beta-catenin (CTNNB1), a key component of the WNT
pathway and driver of epithelial–mesenchymal transition
(Fig. 5b) [43]. AXIN2, another key member of the WNT
signaling pathway [44], was also among the top identi-
fied HMRs and is, together with an additional illustrative
example, displayed in Fig. 5c, d. Importantly, these find-
ings were validated in an independent cohort of colorec-
tal metastasis samples (n = 24) using DNA methylation
microarray analysis (Student’s t-test, p < 0.05; Fig. 5e, f ).
Thus, these findings suggest that large cancer-specific
HMRs are likely candidate markers for identifying se-
quences that could act as de novo activators in a super-
enhancer-like manner.
Conclusions
Overall, our findings indicate that super-enhancers,
regulatory regions critical for cell identity and function,
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are partially regulated by their CpG methylation status
in normal cells, and that they are targeted by specific ab-
errant DNA methylation events in cancer, with putative
effects for the expression of the downstream-controlled
genes. Further, we determined spatial differences of
healthy and transformed DNA methylation profiles
within these large enhancer clusters, suggesting local dif-
ferences in activity in super-enhancer regions.
We hypothesize that local changes in TF binding act
on super-enhancer DNA methylation profiles with sub-
sequent effects on target gene expression. Accordingly,
super-enhancer DNA methylation levels indicate regula-
tory activity and, moreover, point to implicated TFs. In
cancer, the perturbed expression of key TFs establishes
novel super-enhancers that drive oncogene expression, a
scenario that we partially delineated through the identifi-
cation of FOXQ1 as a putative factor driving the differ-
ential DNA methylation at colorectal cancer-specific
super-enhancers and the overexpression of key onco-
genes, such as MYC and RNF43.
Our results also emphasize that developing more ex-
tensive catalogues of human DNA methylomes at base
resolution would help us gain a better understanding of
the regulatory functions of DNA methylation beyond
those of the most widely studied proximal promoter
gene regions.
Materials and methods
Whole genome bisulfite sequencing
Cancer cell lines were obtained from the American Type
Culture Collection (ATCC) and cultivated according to
the provider’s recommendations. All primary samples
analyzed in this study were approved for research use by
the respective ethics committees and were evaluated by
trained personal before entering this study. DNA from
cell lines or fresh frozen healthy and tumor samples was ex-
tracted using Phenol:Chloroform:Isoamylalcohol (Sigma).
We spiked genomic DNA (1 or 2 μg) with unmethy-
lated λ DNA (5 ng of λ DNA per μg of genomic DNA)
(Promega). We sheared DNA by sonication to 50–500 bp
with a Covaris E220 and selected 150- to 300-bp frag-
ments using AMPure XP beads (Agencourt Bioscience
Corp.). We constructed genomic DNA libraries using the
TruSeq Sample Preparation kit (Illumina Inc.) following
Illumina’s standard protocol. After adaptor ligation, we
treated DNA with sodium bisulfite using the EpiTect Bi-
sulfite kit (Qiagen) following the manufacturer's instruc-
tions for formalin-fixed and paraffin-embedded tissue
samples. We performed two rounds of conversion to
achieve >99 % conversion. We enriched adaptor-ligated
DNA through seven cycles of PCR using the PfuTurboCx
Hotstart DNA polymerase (Stratagene). We monitored
library quality using the Agilent 2100 BioAnalyzer and de-
termined the concentration of viable sequencing fragments
(molecules carrying adapters at both extremities) by
quantitative PCR using the Library Quantification Kit
from KAPA Biosystems. We performed paired-end
DNA sequencing (two reads of 100 bp each) using
the Illumina HiSeq 2000.
Sequencing quality was assessed using the Illumina
Sequencing Analysis Viewer and FastQC software (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc). We
ensured the raw reads used in subsequent analyses were
within the standard parameters set by the Illumina proto-
col. Positional quality along the reads was confirmed to be
QC > 30, and we excluded biases towards specific motifs
or GC-enriched regions in the PCR amplification or
hybridization. Sequence alignment and DNA methylation
calling of WGBS reads were performed using Bismark
V.0.7.4 software [45]. SAM/BAM and BED file handling
was done using SAMtools [46], BEDtools [47] and Tabix
[48]. Statistical analysis and graphical representation were
performed with R [49] and multicore and ggplot2 libraries.
We smoothed the DNA methylation profiles using a pre-
viously described method for processing WGBS data [50].
Briefly, the method assumes that the DNA methylation
profile is defined by a varying function of the genomic lo-
cation that can be estimated with a local likelihood
smoother. We used hg19 as the reference genome and re-
trieved genomic information from Biomart [51] and GEN-
CODE V.16 [52]. The TSS was considered to be the most
upstream base of all the annotated transcript variants of
the gene. The DNA methylation data sets for the two breast
cancer cell lines (MDA-MB-468PT and MDA-MB-468LN)
were previously published and are available under accession
code GSE56763, Gene Expression Omnibus (GEO).
Hypomethylated regions
HMRs were identified as previously described [22].
Briefly, the raw methylated and unmethylated read
counts of each CpG site, modeled with a beta-binomial
distribution, provided the input for a hidden Markov
segmentation model with two states (high and low
methylation). Subsequently, a score was computed for
each identified hypomethylated region as the number of
CpG sites minus the sum of their methylation values.
Further, the resulting regions were filtered on the basis
of the 99th percentile of the score obtained by randomly
permuting CpG sites. Differential DNA methylation in
super-enhancers was calculated as difference (δ) in
HMR occupancy (regions overlapping HMRs) between
two samples.
In order to identify large HMRs, we followed a similar
strategy to that described for identifying histone mark-
defined super-enhancers [11], identifying regions that
are substantially larger than their normal counterparts.
We initially extracted HMRs with an average smoothed
DNA methylation level of <0.2 and sorted the regions by
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genomic size. Secondly, we scaled the size and sorting
index to map them to values over a 0–1 range. We then
plotted the scaled region size (y axis) against the scaled
region index (x axis) and examined a subset of the data
(above the 90th percentile of size, high-scaled region
index) and fitted a linear model with the log of the
scaled size as outcome and the logistically transformed
scaled index as predictor. Using the fitted parameter
values, we reverted the variable transformation and iden-
tified the region index for which the derivative of the
curve was 1 (i.e., a line with slope of 1 was the tangent
to the curve). HMRs above this point were defined as
large HMRs. This procedure was performed for each
sample separately.
DNA methylation of super-enhancers
Super-enhancer coordinates were obtained from [11].
For the set of genomic regions defined as super-
enhancers, we extended to each side by 50 % of the total
length to include equally sized flanking regions in down-
stream analyses. Further, we scaled the position of each
region to the center (0), the edges of the original region
(−1 and 1), and the edges of the extended region (−2
and 2). We then retrieved the smoothed methylation in-
formation for each CpG inside the super-enhancers and
flanking regions. Differential DNA methylation levels in-
side super-enhancers and flanking regions were analyzed
by Fisher’s exact test, classifying CpGs as hypomethy-
lated (<0.33 DNA methylation) or hypermethylated
(>0.66 DNA methylation). Tissue-specificity of the DNA
methylation profiles within super-enhancers was deter-
mined by assessing the tissue-matched DNA methylation
profile, as described above, and their characteristics in
an unmatched tissue context. Differences in DNA
methylation (flanking region versus super-enhancer re-
gion) between tissues were analyzed by ANOVA.
WGBS-based tissue-specific hypomethylated super-
enhancers were defined by identifying super-enhancers
with an absolute HMR occupancy >20 % and a differ-
ence in HMR occupancy between the corresponding
tissue and the remaining normal tissues >10 %. Each of
these selected regions was considered as validated if the
average beta value (HumanMethylation450 BeadChip)
in the corresponding tissue samples was <33 % and the
Student’s t-test FDR comparing the corresponding tis-
sue samples against the remaining samples was <0.05.
ChIP-sequencing data of the histone mark H3K27ac
were retrieved from [11]. We computed the H3K27ac
signal (ChIP versus input) and averaged the smoothed
DNA methylation values in 50-bp windows. To define
associations between histone signals and DNA methy-
lation, we performed a Wilcoxon rank-sum test for
the H3K27ac signal between hypomethylated (average
<0.33) and hypermethylated (average >0.66) windows.
Subsequently, we fitted a multivariate linear model
with H3K27ac signal as response variable, DNA
methylation status (hypo/hyper) and CpG density as
predictors to assess the impact of CpG density on the
association.
Differential DNA methylation analysis in cancer was
done by computing the proportion of super-enhancers
covered by HMRs. For each cancer sample and super-
enhancer, we calculated the difference in HMR occu-
pancy (δ HMR; cancer versus corresponding normal
tissue). In order to assess overall differences between
normal and cancer samples in super-enhancers, we
performed a paired t-test for the reduction in DNA
methylation (DNA methylation flanking super-enhancers
versus DNA methylation inside super-enhancers) between
the normal and cancer samples.
Expression analysis
The relationship between DNA methylation and gene
expression was assessed using data obtained from RNA
sequencing and public data sets. Raw RNA sequencing
FASTQ reads from the breast cancer cell lines
(MCF10A, MDA-MB-468PT and MDA-MB-468LN)
were aligned against the human hg19 reference sequence
using the TopHat read-mapping algorithm [53]. Conver-
sion to BAM format was carried out using SAMtools
[46]. Counts of alignments for each gene using BAM
files were generated using BEDtools multicov [47]. In a
subsequent analysis, the non-transformed cell line
MCF10A was considered as control. Data from primary
tumor samples were obtained from TCGA data portal
(https://tcga-data.nci.nih.gov/tcga/). The analyzed sam-
ples included 110 normal breast samples and 30 matched
invasive breast carcinomas (BRCAs), 12 normal colon and
258 adenocarcinomas (COADs), and 57 matched normal
lung and adenocarcinomas (LUADs). To study the associ-
ation of super-enhancer DNA methylation and gene ex-
pression, we obtained TCGA RNA-sequencing data (level
3) at the gene level and performed a Spearman’s correl-
ation test. Correlation analysis of gene expression and dif-
ferential DNA methylation (normal versus cancer, δ > 0.1)
were performed using a Spearman’s correlation test. Alter-
natively, we assigned the super-enhancers to the closest
gene TSS, excluding those super-enhancers without a TSS
within 1 Mb. We fit a log-linear model with RNA-
Sequencing by Expectation Maximization-normalized gene
expression as the response variable and average super-
enhancer DNA methylation as predictor. The association
between differential super-enhancer DNA methylation and
gene expression was determined by fitting a linear model
with the log fold-change of gene expression (cancer versus
normal) as response and the δ HMR occupancy for all the
super-enhancers gaining DNA methylation (δ HMR occu-
pancy >0 %) or by Spearman’s correlation test.
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For microRNA quantification the Taqman microRNA
Reverse Transcription kit and microRNA specific Taq-
man assays (Applied Biosytems) were used. The expres-
sion level was evaluated by real-time quantitative PCR
using the 7900HT Fast Real-Time PCR System (Applied
Biosystems). Expression values are reported as relative
microRNA expression levels normalized to RNU6B
expression.
Infinium HumanMethylation450 BeadChip
DNA from fresh frozen healthy and tumor samples
was extracted using phenol:chloroform:isoamylalcohol
(Sigma). All DNA samples were assessed for integrity,
quantity and purity by electrophoresis in a 1.3 %
agarose gel, picogreen quantification, and nanodrop
measurements. All samples were randomly distributed
into 96-well plates. Bisulfite conversion of 500 ng of
genomic DNA was done using the EZ DNA Methyla-
tion Kit (Zymo Research), following the manufacturer’s
instructions. Bisulfite-converted DNA (200 ng) were used
for hybridization on the HumanMethylation450 BeadChip
(Illumina).
The HumanMethylation450 BeadChip data were
processed using the Bioconductor minfi package [54].
We performed the “llumina” procedure that mimics the
method of GenomeStudio (Illumina); specifically, it per-
forms a background correction and a normalization
taking as a reference the first array of the plate. We
removed probes with one or more single nucleotide
polymorphisms (SNPs) with a minor allele frequency
(MAF) >1 % (1000 Genomes) in the first 10 bp of
the interrogated CpG, based on [55]. In order to
minimize batch effect, we used ComBat normalization
[56]. The methylation level (β) for each of the
485,577 CpG sites was calculated as the ratio of
methylated signal divided by the sum of methylated
and unmethylated signals plus 100. After the
normalization step, we removed probes related to X
and Y chromosomes. All analyses were performed in
human genome version 19 (hg19).
We identified HMRs within super-enhancer-overlapping
probes (≥3) on the BeadChip and computed the average
DNA methylation level for super-enhancers (HMR located
probes) per sample (tissue-wise). Differences in DNA
methylation levels at hypomethylated super-enhancer re-
gions were determined using Student’s t-test (FDR < 0.05).
Selected super-enhancers were hierarchically clustered
using Manhattan distance and median clustering algo-
rithms. Finally, we assessed the BeadChip-based CpG
methylation levels of common differentially methylated
super-enhancers and performed hierarchical clustering
using Canberra distance and Ward clustering algo-
rithms with CpG-level data. The DNA methylation
data for lung adenocarcinomas and lung squamous
cell carcinomas were previously published and are
available under accession code GSE39279, Gene Ex-
pression Omnibus (GEO).
The DNA hypomethylation observed at cancer-related
super-enhancers was validated using data obtained from
TCGA data portal (https://tcga-data.nci.nih.gov/tcga/).
The analyzed samples included 41 matched normal
and colorectal cancer samples. We obtained TCGA
DNA methylation data from the HumanMethyla-
tion450 BeadChip (level 3) and averaged DNA methy-
lation levels per super-enhancer containing ≥3 probes
in the hypomethylated region. Significant differences
between normal and cancer samples were assessed
using a Wilcoxon test, with values of p < 0.01 consid-
ered to be significant.
CNV analysis
To test for biases in DNA methylation analysis due to
CNV in cancer samples, we applied two independent ap-
proaches based on DNA methylation or SNP array data.
For the 714 primary cancer samples analyzed using the
HumanMethylation450 BeadChip, we performed a copy
number analysis comparing cancer and normal samples
using Bioconductor and the CopyNumber450K R package
for CNV inference using the Illumina 450 k DNA methy-
lation assay. We defined a region to be aberrant if >50 %
of the region presented a significant copy number alter-
ation as reported by the software (FDR < 0.05). Alterna-
tively, for TCGA data set of colorectal adenocarcinomas
[17], we used level 3 CNV data and defined a region to be
aberrant if >50 % of the super-enhancer region presented
copy numbers <1.5 or >2.5. For the WGBS cancer sam-
ples, we hybridized genomic DNA on the HumanOmni5
SNP array (Illumina) and performed a copy number ana-
lysis based on GenomeStudio software (V.2011.1) routines
for the HumanOmni5-4v1_B chips.
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